Month: September 2021

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event: Cantor Virtual Global Healthcare ConferenceTuesday, September 28, 2021Fluidigm presentation at 2:00 p.m. ET, 11:00 a.m. PT A live webcast of the company’s presentation and subsequent replay will be available in the Events & Presentations section of the Fluidigm® investor website. The webcast will be archived for 90 days following the live presentation. About Fluidigm Fluidigm (Nasdaq:FLDM)...

High-strength mold insert for air vents produced in Certified M789 (A)High-strength mold insert for air vents produced with metal additive manufacturing in Certified M789 (A) cobalt free tool steel. Integrated conformal cooling channels manage heat dissipation, achieve uniform cooling, reduce warping and deformation while achieving better overall injection molding economics.Company facilitating additive manufacturing of high-strength, corrosion-resistant parts in Certified Scalmalloy (A) & Certified M789 (A) on Direct Metal Printing platform Application Innovation Group offers service to help customers certify materials, accelerating innovation and time to marketROCK HILL, S.C., Sept. 02, 2021 (GLOBE NEWSWIRE) — 3D Systems (NYSE:DDD) today announced two additions to its industry-leading materials portfolio...

SAN CARLOS, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:2021 Virtual Wells Fargo Healthcare ConferenceFireside Chat Thursday, September 9 at 4:40 p.m. Eastern TimeH.C. Wainwright 23rd Annual Global Investment Conference On-demand presentation available beginning Monday, September 13 at 6:00 a.m. Eastern TimeLive audio webcasts of the Wells Fargo fireside chat, as well as the on-demand H.C. Wainwright presentation can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. Replays of both the Wells Fargo and H.C. Wainwright presentations will be available on the Company’s website for two weeks following the...

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company’s management team will be presenting at the following investor conferences:2021 Virtual Wells Fargo Healthcare ConferenceThursday, September 9 at 9:20 a.m. ETH.C. Wainwright 23rd Annual Global Investment ConferenceMonday, September 13 at 7:00 a.m. ETBaird 2021 Global Healthcare ConferenceTuesday, September 14 at 9:40 a.m. ETThe webcasts of the presentations will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcasts, it is recommended that...

South Korean steelmaker to supply to Array’s global projects ALBUQUERQUE, N.M., Sept. 02, 2021 (GLOBE NEWSWIRE) — Array Technologies (NASDAQ: ARRY) (“Array”), one of the world’s largest manufacturers of ground-mounted systems used in solar energy projects, today announced it has entered into a multi-year supply arrangement with POSCO, one of the world’s largest steelmakers, to diversify and strengthen its global supply chain. Array will now have access to POSCO’s proprietary PosMAC® material, an alloy coated corrosion resistant steel. POSCO will cooperate with a Korean local fabricator to convert the products into components for use at Array’s global solar project sites. POSCO’s South Korean headquarters will position Array to serve customers in the U.S., Australia, and other emerging solar markets more efficiently with a stable...

VANCOUVER, British Columbia, Sept. 02, 2021 (GLOBE NEWSWIRE) — OOOOO Entertainment Commerce Limited (“OOOOO” or the “Company”) (OOOO:TSXV), a mobile commerce platform, is pleased to announce that the Company has appointed Tom Judge to the role of Chief Operating Officer. Mr. Judge brings a wealth of experience to OOOOO including over twelve years in e-commerce operations and finance. Tom will be responsible for operations, partner success and international expansion, overseeing the business teams to optimize processes and ensure sustainable company growth. Tom brings management experience from Rocket Internet where he led their operations, technical and customer service teams. In addition to Rocket Internet, Tom played an instrumental role in several highly successful technology start-ups that have either been acquired or gone...

SACRAMENTO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer of specialty alcohols and essential ingredients, today announced that Chief Executive Officer, Mike Kandris and Chief Financial Officer, Bryon McGregor will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021, set to go live at 4:00am PT/ 7:00am ET. Management will meet one-on-one with institutional investors during the day. To schedule a one-on-one meeting or for more information about the conference, please contact your H.C. Wainwright representative. Presentation materials and the webcast will be posted on the Investor Relations portion of the company website. About Alto Ingredients, Inc. Alto Ingredients, Inc. (ALTO), formerly known as Pacific Ethanol, Inc., is a leading...

TORONTO and CHICAGO, Sept. 02, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Medexus’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021, at 7:00 AM Eastern Time. The webcast can be accessed here and on the investor relation section of the Medexus website at https://www.medexus.com/en_US/investors. Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference. About...

This expanded use by SANDAG reinforces the US market reach of mdf commerce in the strategic sourcing sector. MONTREAL, Sept. 02, 2021 (GLOBE NEWSWIRE) — mdf commerce inc. (TSX:MDF), a leader in SaaS commerce technology solutions, announces today that the San Diego Association of Governments (SANDAG), a regional government agency that represents 18 cities and the County of San Diego, plans to expand its use of the platform to encompass its small and disadvantaged vendor program and its grant distribution program. In addition to the existing 10-year agreement with mdf commerce for its end-to-end contract lifecycle management (CLM) solution, SANDAG has implemented tailored features and functionality from the mdf commerce Strategic Sourcing suite and is using the certification and pre-qualification modules to manage its diversity and...

-Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS- LOS ANGELES, Sept. 02, 2021 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the Company will present final data from its HOPE-2 clinical trial with asset CAP-1002 at this year’s World Muscle Society Virtual Congress (WMS). HOPE-2 is Capricor’s randomized, double-blind, placebo-controlled, Phase II clinical trial in 20 patients with late-stage Duchenne muscular dystrophy (DMD), conducted at nine sites in the U.S. The late-breaking results will be presented in an oral session on Sept....